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Abstract
The study was aimed to the biological effectiveness of the proton scanning beam of
the first Russian medical facility. The clonogenic assay of B-16 tumor cells was used
as a test system. Cell irradiation was carried out in a suspension condition in a water
phantom. Single and three-field exposures were studied. The dose interval was 2-8
Gy. The energy range from 47.5 to 92.0 MeV was used for the Bragg peak formation.
The relative biological effectiveness of protons comparing to gamma-rays was 1.2
for single-field and 1.5 for three-field irradiation. The results obtained agree with
literature data related to the used cell culture (B-16) and linear energy transfer range
(3÷8 keV/µm).
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1. Introduction
The prospect of the clinical application of high-energy protons was first suggested
by Robert Wilson in 1946, and the first patients were treated with a proton beam at
the Berkeley Laboratory of Radiation Research in California in the early 1950s [7]. Cur-
rently in the world (excluding Russia) there are 62 proton therapy centers in operation,
located in 17 countries (USA, Japan, Germany, Italy, China, France, Austria, etc.) [16].
According to the forecasts, its number will increase in the next few years [18]. Up to
day 130 000 patients have been treated with protons.
From the point of view of radiotherapy, the key feature of protons, as well as other
heavy charged particles, is the specific distribution of the absorbed dose. The increase
in energy losses at the end of the particle track within the biological tissue results in
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formation of the Bragg peak, the place where the tissue receives the maximal dose.
The position of this peak depends on the energy of the particles. Thus, if the proton
beam contains particles with different but defined energies, it is possible to irradiate a
given volume in the same dose using spread-out Bragg peak (SOBP).
A number of studies, including recent ones, have shown that the value of the relative
biological efficiency (RBE) is not constant and depends on the initial beam energy, the
linear energy transfer (LET) associated with it, the dose per fraction, the position in
SOBP, tissue radiosensitivity (α/β ratio) and biological effect estimation method [3, 6,
9-15, 17].
In Russia, up to the present day, three centers of proton therapy are in operation:
in Dubna ( JINR), St. Petersburg (PNPI) and from 2016 in A. Tsyb Medical Radiological
Research Center (MRRC). The source of a proton pencil scanning beam in MRRC was
developed by ZAO “Protom”. The proton therapy center in MRRC could be considered
as the first Russian medical facility.
The purpose of this studywas to determine the RBE of the ”Prometheus” installation
proton beam in experiments on the culture of melanoma cells B-16 in case of single
and three-field irradiation.
2. Materials and Methods
2.1. B-16 cells
The biological object used in the study was the culture of mouse melanoma cells
B16F10. The characteristic of the cell line is given in the previously published work
of the authors [2]. The culture was grown in a monolayer condition in culture flasks
with a surface area of 25 cm2 (Corning, USA) in RPMI-1640 medium (PanEco, Russia)
with addition of 10% fetal bovine serum (Biosera, France) and 0.01 mg/ml gentamicin
(PanEco, Russia). The cells were cultured in a CO2 incubator (MCO-5AC, Sanyo, Japan)
at +37∘C and 5% CO2.
On the day of the experiment, the cells were removed from the plastic with a mix-
ture of versen (0.02%, PanEco, Russia) and trypsin (0.25%, PanEco, Russia) in 1:1 ratio.
Then the cells were resuspended in RPMI-1640 medium containing 10% of serum. The
cells were counted using hemocytometer and diluted to the appropriate concentration
(300-600 thousand in 1 ml). For irradiation, the cell suspension was dispensed into
micro centrifuge tubes (volume 1.5 ml, Genfollower, China) up to 1.3 ml. Before and
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after irradiation, the cells were kept on ice. The irradiation was carried out at room
temperature.
2.2. Clonogenic assay
After the irradiation, the clonogenic activity of the cells was determined. For this, the
cells were resuspended, diluted to the proper concentration and plated (1000 to 72,000
cells per dish, depending on the dose of irradiation) in 100 mm Petri dishes (Corning,
USA) with medium RPMI-1640 supplemented with 10% of fetal bovine serum. The
cells were incubated in a CO2 incubator for 7-8 days before the formation of visible
colonies. After the incubation, the culture medium was removed; the colonies were
stained with a 2% solution of methylene blue in 50% ethanol. Colony counting was
conducted using Scan 100 counter (Interscience, France). The clonogenic cell fraction
was expressed as a ratio to the number of seeded cells and adjusted to the survival of
the cells in the control.
2.3. Source of protons
Irradiation was carried out at the ”Prometeus” installation (protons acceleration is
performed by the synchrotron, the beam output – horizontal) in the water phantom.
The distance from the front wall of the phantom to the source was 70 cm. Verification
of the phantom position was carried out from two directions (0 and 90 degrees). The
location of the phantom on the object table of the positioning system is shown in Fig.
1. A tube with a cell suspension after shaking (V-1 Plus, Biosan, Latvia) was placed in
the central port of the water phantom.
Proton irradiationwas conductedwith single and three fields (0, 90 and 180∘). Before
the experiments, an irradiation plan was calculated. The dose of irradiation was 2 Gy.
The volume of PTV (Planning Target Volume) was 24.2 cm3 for irradiation from one
field and 18.5 cm3 in case of three fields. Doses of 2, 4, 6 and 8 Gy were used for
irradiation. The same irradiation plan was repeated 2, 3 and 4 times was used. The
pause between the fractions did not exceed 10 s for single filed irradiation and 20 s –
in case of three-field exposure. The average dose rate (for the time from the start of
irradiation to the system signal of its end) for one field was 2.2 Gy/min, for three fields
– 0.84 Gy/min.
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Figure 1: Water phantom with a test object on the table of the positioning system.
2.4. The source of photons
The standard radiation was the γ-rays of 60Co with average energy 1.25 MeV. The dose
rate was 1 Gy/min. The doses of exposure were 2, 4, 6, 8, 10 Gy. The tubes with the
cell suspension after shaking were irradiated without phantom.
2.5. Statistics
Biological experiments were performed in 4 replicates. The received data of cell sur-
vival processed using statistical software R 3.4.1 and Veusz 2.0.1.
Dose dependency fittingwas conducted using linear-quadraticmodel (1). Conformity
of experimental data to the model was evaluated by χ2 criterion.
𝑆 = 100 ⋅ exp (−𝛼 ⋅ 𝑥 − 𝛽 ⋅ 𝑥2) (1)
Dose measurement error for protons and photons according to documentation was
within 5%. The true error of the absolute survival values was 12%; the error of the RBE
estimation according to the linear-quadratic model was 10%.
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Figure 2: Dependence of B-16 cells survival according to its clonogenic activity on the dose: 1-γ-irradiation
(closed symbols), 2 - theoretically expected survival curve after proton irradiation, 3 - protons in single-
field irradiation, 4 - combined data on protons (open symbols), 5 - protons in three-field irradiation.
3. Results
Dose dependences of clonogenic activity of murine melanoma B-16 cells after irradi-
ation with protons and gamma radiation are shown on Fig. 2.
Figure 2 shows that the curves of protons are located below the γ-ray curve and
theoretically expected for protons due to the higher biological efficacy. Irradiation
from three directions was more effective than with one due to more complex LET
distribution and more uniform dose distribution. The value of the LET of protons was
within 3-8 keV/μm; in case of gamma-rays – 0.3 keV/μm. The RBE was higher than
generally accepted 1.1 value both for irradiation from one and three directions: at the
level of 10% survival the RBE is 1.2 for one field irradiation and 1.5 in case of three
fields.
4. Discussion
The studies of biological effectiveness of protons continue for a long time, but there is
no certain answer about the RBE issue. According to T. Friedrich et al. data [4] obtained
for the most frequently used cell cultures, the RBE of protons for of 10% survival in
the range of LET values of 3÷8 keV/μm varies from 0.95 to 1.47.
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Figure 3: Dose dependence of the survival of B-16 melanoma cells: 1-γ -irradiation, 2-protons on the
plateau according to Ibanez et al. [8], 3 - protons in single-field irradiation, 4 - protons in the Bragg peak
according to Ibanez et al. [8], 5 - protons in three-field irradiation.
In studies conducted by I. Ibanez et al. [8] the RBE value of protons at a 10% survival
of melanoma B16 cells was 1.0 in the plateau region (LET – 3.4 keV/μm), and 1.6 in the
Bragg peak (LET – 14 keV/μm). Since in our study the LET value varied from 3 to 8
keV/μm, we could assume that our data coincided with the results of I. Ibanez et al.
(Fig. 3).
With the use of scanning proton beams, the LET variations could be extremely high
due to the intensitymodulation [6]. In case of irradiationwith several directions (fields)
further complications in the regions of high average LET may arise [5]. If the long-
run objective is the assessment of RBE to select the patient exposure scheme, the
main task is to find a balance between this uncertainty and the clinical relevance in
correcting RBE values.
5. Conclusion
To date, studies on assessment of proton biological effectiveness has been mainly
carried out using passive scattering techniques, and a small amount of data is available
for pencil scanning beams. The results of our studies show that the experimental RBE
value of protons differs from the recommended 1.1 by the International Commission
on Radiation Units and Measurements 1.1.




This work was carried out within the framework of the state task of A. Tsyb MRRC –
branch of the National Medical Research Center for Radiology of the Ministry of Health
of the Russian Federation in 2015-2017 [1].
Acknowledgments
The authors are grateful to employees of the MRRC proton therapy center for the
invaluable help in carrying out this research.
References
[1] Kaprin A.D., Galkin V.N., Zhavoronkov L.P., et al. Synthesis of fundamental and
applied research is the basis for ensuring a high level of scientific results and their
introduction into medical practice.// Radiation and Risk. – 2017. – Т. 26. –N. 2. – P.
26-40.
[2] Beketov E., Isaeva E., Koryakin S., et al. The study of biological effectiveness of U-
70 accelerator carbon ions using melanoma B-16 clonogenic assay. // Rad. Applic.
– 2017. – V. 2. – I. 2. – P.90-93.
[3] Cuaron J.J, Chang C., Lovelock M., et al. Exponential increase in relative biological
effectiveness along distal edge of a proton Bragg peak as measured by deoxyri-
bonucleic acid double-strand breaks. // Int J Radiat Oncol Biol Phys. – 2016. – V.95.
– I.1. –P.62-69.
[4] Friedrich T., Scholz U., Elsässer T., et al. Systematic analysis of RBE and related
quantities using a database of cell survival experiments with ion beam irradiation.
// J Radiat Res. – 2013. – 54. – I. 3. – P. 494-514.
[5] Giovannini G., Bohlen T., Cabal G., et al. Variable RBE in proton therapy: comparison
of differentmodel predictions and their influence on clinical-like scenarios. // Radiat
Oncol. –2016. – V.11. – P. 68.
[6] Grassberger C, Paganetti H. Varying relative biological effectiveness in proton
therapy: knowledge gaps versus clinical significance.// Acta Oncol. –2017. – V.56.
– I.6. –P.761-762.
[7] Hall E. Protons for radiotherapy: a 1946 proposal.//Lancet Oncol. –2009. – V.10. – I.2.
–P.196.
DOI 10.18502/keg.v3i3.1630 Page 315
 
AtomFuture-2017
[8] Ibanez I., Bracalente C., Molinari B., et al. Induction and Rejoining of DNA Double
Strand Breaks Assessed by H2AX Phosphorylation inMelanoma Cells Irradiatedwith
Proton and Lithium Beams. // Int J Radiat Oncol Biol Phys. –2009. – V.74. – I. 4. – P.
1226-1235.
[9] Jones B. Towards achieving the full clinical potential of proton therapy by inclusion
of LET and RBE models. Cancers (Basel). – 2015. – V.7. – I.1. –P.460-480.
[10] Keta O., Todorovic D., Popovic N., et al. Radiosensitivity of human ovarian carcinoma
and melanoma cells to γ-rays and proton. // Arch Med Sci. – 2014. – V.10. – I.3. –
P.578-586.
[11] Maeda K., Yasui H., Matsuura T., et al. Evaluation of the relative biological
effectiveness of spot-scanning proton irradiation in vitro. // J Radiat Res. – 2016.
– V.57. – I.3. – P.307-311.
[12] Marshall T.I., Chaudhary P., Michaelidesova A., et al. Investigating the implications
of a variable RBE on proton dose fractionation across a clinical pencil beam scanned
spread-out Bragg peak. // Int J Radiat Oncol Biol Phys. – 2016. – V.95. – I.1. – P.70-77.
[13] Matsumoto Y., Matsuura T., Wada M., et al. Enhanced radiobiological effects at the
distal end of a clinical proton beam: in vitro study. // Journal of Radiation Research.–
2014. – V.55. – I. 4. –P.816-822.
[14] Michaelidesova А., Vachelova J., Puchalska M., et al. Relative biological effective-
ness in a proton spread-out Bragg peak formed by pencil beam scanning mode. //
Australas Phys Eng Sci Med. – 2017. – V.40. – I. 2. –P.359-368.
[15] Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy.
Variations as a function of biological endpoints, dose, and linear energy transfer. //
Phys Med Biol. – 2014. – V.59. – I.22. – P.4194-4272.
[16] Particle Therapy Centers [Internet]. Particle Therapy Co-Operative Group [cited 2017
Nov 3]. Available from: https://www.ptcog.ch/.
[17] Slonina D., Biesaga B., Swakon J., et al. Relative biological effectiveness of the 60-
MeV therapeutic proton beamat the Institute of Nuclear Physics (IFJ PAN) in Krakow,
Poland. // Radiat Environ Biophys. – 2014. – V.53. – I.4. – P.745-754.
[18] Tommasino F, Durante M. Proton Radiobiology. // Cancers. – 2015. – V.7. –P.353-381.
DOI 10.18502/keg.v3i3.1630 Page 316
